Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Outcomes and clinical characteristics of the compassionate use of plitidepsin in COVID-19 patients with solid tumours, haematological malignancies or anti-CD20 antibody treatment.
Infect Dis (Lond). 2024 May 14:1-6. doi: 10.1080/23744235.2024.2351043. Online ahead of print.
Infect Dis (Lond). 2024.
PMID: 38743059
Outcomes and clinical characteristics of the compassionate use of plitidepsin for immunocompromised adult patients with COVID-19.
Aguareles J, Fernández PV, Carralón-González MM, Izquierdo CF, Martí-Ballesteros EM, Fernández VP, Sotres-Fernandez G, García-Delangue T, LaPetra RGV, Sánchez-Manzano MD, Gutiérrez C, García-Coca M, Carnevali-Ruiz D, Barrena-Puertas R, Luque-Pinilla JM, Lloris R, Luepke-Estefan XE, López-Martín JA, Jimeno JM, Guisado-Vasco P.
Aguareles J, et al. Among authors: luepke estefan xe.
Int J Infect Dis. 2023 Oct;135:12-17. doi: 10.1016/j.ijid.2023.07.011. Epub 2023 Jul 21.
Int J Infect Dis. 2023.
PMID: 37481109
Free article.
Item in Clipboard
Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer.
Awada AH, Boni V, Moreno V, Aftimos P, Kahatt C, Luepke-Estefan XE, Siguero M, Fernandez-Teruel C, Cullell-Young M, Tabernero J.
Awada AH, et al. Among authors: luepke estefan xe.
ESMO Open. 2022 Dec;7(6):100651. doi: 10.1016/j.esmoop.2022.100651. Epub 2022 Nov 28.
ESMO Open. 2022.
PMID: 36455505
Free PMC article.
Clinical Trial.
Item in Clipboard
Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors.
Calvo E, Sessa C, Harada G, de Miguel M, Kahatt C, Luepke-Estefan XE, Siguero M, Fernandez-Teruel C, Cullell-Young M, Stathis A, Drilon A.
Calvo E, et al. Among authors: luepke estefan xe.
Invest New Drugs. 2022 Dec;40(6):1263-1273. doi: 10.1007/s10637-022-01281-z. Epub 2022 Aug 10.
Invest New Drugs. 2022.
PMID: 35947247
Free PMC article.
Clinical Trial.
Item in Clipboard
Metabolic Disposition of Lurbinectedin, a Potent Selective Inhibitor of Active Transcription of Protein-Coding Genes, in Nonclinical Species and Patients.
Aviles P, Altares R, van Andel L, Lubomirov R, Fudio S, Rosing H, Márquez Del Pino FM, Tibben MM, Benedit G, Nan-Offeringa L, Luepke Estefan XE, Francesch A, Zeaiter A, Cuevas C, Schellens JHM, Beijnen JH.
Aviles P, et al. Among authors: luepke estefan xe.
Drug Metab Dispos. 2022 Apr;50(4):327-340. doi: 10.1124/dmd.121.000668. Epub 2022 Jan 18.
Drug Metab Dispos. 2022.
PMID: 35042701
Item in Clipboard
Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leukemia.
Guisado-Vasco P, Carralón-González MM, Aguareles-Gorines J, Martí-Ballesteros EM, Sánchez-Manzano MD, Carnevali-Ruiz D, García-Coca M, Barrena-Puertas R, de Viedma RG, Luque-Pinilla JM, Sotres-Fernandez G, Fernández-Sousa JM, Luepke-Estefan XE, López-Martín JA, Jimeno JM.
Guisado-Vasco P, et al. Among authors: luepke estefan xe.
J Hematol Oncol. 2022 Jan 10;15(1):4. doi: 10.1186/s13045-021-01220-0.
J Hematol Oncol. 2022.
PMID: 35012608
Free PMC article.
Item in Clipboard
Plitidepsin for the management of a cancer patient infected with SARS-CoV-2 while receiving chemotherapy.
Guisado-Vasco P, González-Cortijo L, D'Errico G, Serrera-Alvarez A, Sotres-Fernandez G, García-Coca M, Fernández-Sousa JM, Luepke-Estefan XE, López-Martín JA, Jimeno JM.
Guisado-Vasco P, et al. Among authors: luepke estefan xe.
Ann Oncol. 2021 Oct;32(10):1295-1297. doi: 10.1016/j.annonc.2021.07.003. Epub 2021 Jul 7.
Ann Oncol. 2021.
PMID: 34242743
Free PMC article.
No abstract available.
Item in Clipboard
Cite
Cite